Case number 1:24-cv-01045
Novartis Pharmaceuticals Corporation v. Lupin Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 26, 2024 | 13 | STIPULATION and Proposed Order of Dismissal Without Prejudice, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/26/2024 (nms). (Entered: 11/26/2024) (2) |
| Nov 26, 2024 | 14 | SO ORDERED Granting (D.I. 1664 in 20-md-2930-RGA; D.I. 13 in 24-cv-1045-RGA) Stipulation and Proposed Order of Dismissal Without Prejudice. Signed by Judge Richard G. Andrews on 11/26/2024. Associated Cases: 1:20-md-02930-RGA, 1:24-cv-01045-RGA(nms) (Entered: 11/26/2024) (2) |
| Nov 26, 2024 | N/A | CASE CLOSED per entry of D.I. 14 . (nms) (Entered: 11/26/2024) (0) |
| Nov 26, 2024 | 15 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,096,918. (Attachments: # 1 Order)(nms) (Entered: 11/26/2024) (0) |
| Nov 22, 2024 | N/A | SO ORDERED, re 12 STIPULATION and Proposed Order (*Reset Answer Deadlines: Lupin Atlantis Holdings, S.A. answer due 12/2/2024; Lupin Inc. answer due 12/2/2024; Lupin Limited answer due 12/2/2024; Lupin Pharmaceuticals, Inc. answer due 12/2/2024). Signed by Judge Richard G. Andrews on 11/22/2024. (nms) (Entered: 11/22/2024) (0) |
| Nov 21, 2024 | 10 | NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Lupin Inc., Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Pharmaceuticals, Inc. (Cottrell, Frederick) (Entered: 11/21/2024) (1) |
| Nov 21, 2024 | 11 | NOTICE of Appearance by Alexandra M. Ewing on behalf of Lupin Inc., Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Pharmaceuticals, Inc. (Ewing, Alexandra) (Entered: 11/21/2024) (1) |
| Nov 21, 2024 | N/A | CORRECTING ENTRY: The stipulation to extend filed at D.I. 12 has been removed from the docket as it was not completely formatted. This case is a member case to MDL. No. 20-md-2930-RGA and therefore all filings are required to be duel captioned for the MDL and the member case. Counsel is to revise and refile accordingly. (nms) (Entered: 11/21/2024) (0) |
| Nov 21, 2024 | 12 | STIPULATION and Proposed Order to Extend Time - filed by Lupin Inc., Lupin Atlantis Holdings, S.A., Lupin Limited, Lupin Pharmaceuticals, Inc.. (Ewing, Alexandra) Modified on 11/22/2024 (nms). (Entered: 11/21/2024) (2) |
| Oct 2, 2024 | 6 | WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Atlantis Holdings, S.A. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024) (1) |
| Oct 2, 2024 | 7 | WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Inc. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024) (1) |
| Oct 2, 2024 | 8 | WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Limited waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024) (1) |
| Oct 2, 2024 | 9 | WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Pharmaceuticals, Inc. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024) (1) |
| Sep 25, 2024 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 09/25/2024) (0) |
| Sep 25, 2024 | N/A | Remark: The MDL panel has been advised. (mpb) (Entered: 09/25/2024) (0) |
| Sep 18, 2024 | 1 | COMPLAINT against Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, and Lupin Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-4501085) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(mpb) Modified on 9/25/2024 (nms). (Entered: 09/18/2024) (0) |
| Sep 18, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 09/18/2024) (3) |
| Sep 18, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/6/2024. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/6/2027. (mpb) (Entered: 09/18/2024) (2) |
| Sep 18, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,096,918. (mpb) (Entered: 09/18/2024) (1) |
| Sep 18, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mpb) (Entered: 09/18/2024) (2) |
| Sep 18, 2024 | N/A | No Summons Issued. (mpb) (Entered: 09/18/2024) (0) |
